Study identifier:D6874L00025
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Bioequivalence study of ICI176,334-1 in Japanese healthy male subjects - evaluation of bioequivalence of ICI176,334-1 and Casodex 80 mg tablet -
Healthy
Phase 1
Yes
ICI176,334-1, Casodex 80 mg tablet
Male
48
Interventional
20 Years - 45 Years
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Nov 2013 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Active 1 12 subjects will receive ICI176,334-1 and Casodex 80 mg tablet | Drug: ICI176,334-1 Subject will receive single dose of ICI176,334-1 Drug: Casodex 80 mg tablet Subject will receive single dose of Casodex 80 mg tablet |
Experimental: Active 2 12 subjects will receive ICI176,334-1 and Casodex 80 mg tablet | Drug: ICI176,334-1 Subject will receive single dose of ICI176,334-1 Drug: Casodex 80 mg tablet Subject will receive single dose of Casodex 80 mg tablet |
Experimental: Active 3 12 subjects will receive ICI176,334-1 and Casodex 80 mg tablet | Drug: ICI176,334-1 Subject will receive single dose of ICI176,334-1 Drug: Casodex 80 mg tablet Subject will receive single dose of Casodex 80 mg tablet |
Experimental: Active 4 12 subjects will receive ICI176,334-1 and Casodex 80 mg tablet | Drug: ICI176,334-1 Subject will receive single dose of ICI176,334-1 Drug: Casodex 80 mg tablet Subject will receive single dose of Casodex 80 mg tablet |